Merck sac-TMT improves survival in Phase 3 gastric cancer trial
Life Sciences
Friday, November 20, 2026
- Updated Nov 20, 2026 11:24
Merck said its investigational antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) met the primary endpoint of overall survival in the Phase 3 TroFuse-015 trial in patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who had received at least two prior lines of systemic therapy.
Why it matters: TroFuse-015 is the second positive Phase 3 readout in Merck's TroFuse program and, on the company's account, the first overall survival benefit shown by a TROP2-directed antibody-drug conjugate in this population, strengthening a drug Merck is counting on as Keytruda approaches its patent cliff.
Data as of Merck press release of November 20, 2026, read in full via its republication by American Pharmaceutical Review after the Endpoints News report proved paywalled; the release discloses no hazard ratio or median survival figures. Developing item.
Merck said the global, open-label TroFuse-015 study enrolled 473 patients and randomly assigned them to sac-TMT or one of four treatments of physician’s choice, trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel, and that at the final analysis overall survival improved statistically significantly and clinically meaningfully, with results generally consistent across subgroups regardless of TROP2 expression status. The trial did not meet its secondary endpoint of progression-free survival as assessed by blinded independent central review, objective response favoured sac-TMT but was not formally tested, and the safety profile was consistent with earlier sac-TMT studies with no new signals.
Sac-TMT is a TROP2-directed antibody-drug conjugate developed by Kelun-Biotech, which Merck licenses for development, manufacture and commercialisation outside Greater China. TroFuse-015 is the second positive Phase 3 readout in the TroFuse program, which has 18 ongoing global Phase 3 trials, and Merck said it will present the results at an upcoming medical meeting and share the data with regulatory authorities.
Sources
- Merck Announces TroFuse-015 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoint of Overall Survival (OS) in Third-Line or Later Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma - Merck & Co. via Business Wire - 2026-11-20
- Merck gets another Phase 3 win for sac-TMT, this time in gastric cancer - Endpoints News - 2026-11-20